SM-102: LNP Lipid for mRNA Delivery

Executive Summary. SM-102 is the synthetic lipid heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate, with a reported molecular weight of 710.18 g/mol (product information for SM-102). The C1042 product is supplied at 98.00% purity, verified by mass spectrometry and nuclear magnetic resonance analyses (product information). The product is reported as insoluble in water and DMSO and highly soluble in ethanol at ≥175.8 mg/mL (product information). Lipid nanoparticles are established delivery systems for mRNA vaccines, and their ionizable-lipid component contributes to mRNA association, endosomal interactions, and intracellular release (Wang et al., 2022).

Biological Rationale

Unformulated mRNA is a challenging payload because it must reach the cytosol before translation can occur. An mRNA vaccine delivery system therefore needs to protect the nucleic acid during formulation and transport. It must also support cellular uptake and release from intracellular compartments.

Lipid nanoparticles address these barriers through a multicomponent structure. The reference study describes four common lipid classes: an ionizable lipid, cholesterol, distearoylphosphatidylcholine, and a polyethylene glycol lipid (Wang et al., 2022). Cholesterol affects lipid flexibility and fusogenicity during mixing. Distearoylphosphatidylcholine contributes to particle structure and mRNA release. The polyethylene glycol lipid affects particle stability and size. The ionizable lipid is the formulation component most directly associated with mRNA binding, endosomal membrane interaction, and mRNA release.

SM-102 is used as a synthetic ionizable-lipid component in this design space. Its practical value is therefore formulation-dependent. The molecule is not a complete delivery system by itself. Particle composition, mixing conditions, nucleic-acid loading, buffer environment, and dose can all affect the resulting LNP.

In mRNA vaccine development, the objective is not simply to maximize lipid loading. The formulation must balance encapsulation, particle stability, cell uptake, endosomal escape, tolerability, and antigen expression. This balance explains why an endosomal escape lipid should be evaluated in the complete LNP rather than judged from the isolated compound alone.

Mechanism of Action of SM-102

The available backbone study explains the mechanism at the ionizable-lipid and LNP levels rather than proving a unique molecular pathway for every SM-102 formulation. During LNP formation, lipid molecules aggregate into nanoparticles, and mRNA associates with the resulting lipid structure (Wang et al., 2022). This association enables the particle to carry mRNA through extracellular and intracellular environments.

The ionizable-lipid head group is important because it can interact with negatively charged mRNA during formulation. The same lipid class can also interact with endosomal membranes after cellular uptake. These interactions are linked to mRNA release into the cell in the cited mechanistic framework (Wang et al., 2022).

For SM-102, the appropriate mechanistic interpretation is functional rather than absolute. The compound is selected as an LNP component to support mRNA encapsulation, delivery, and intracellular release. The product description specifically positions SM-102 for cellular uptake and endosomal escape of mRNA (product information for the C1042 kit). That description does not establish that every SM-102 formulation has the same uptake, escape, or expression profile.

This distinction matters for scientific communication. “SM-102 enables mRNA delivery” is a formulation-level statement. “SM-102 alone causes endosomal escape” would be an overstatement because endosomal escape is a property of the assembled LNP, payload, cell type, and experimental conditions.

Evidence & Benchmarks

The strongest directly relevant peer-reviewed evidence in the reference backbone evaluates LNP formulations, computational prediction, and an animal comparison. It does not establish a universal ranking for all ionizable lipids or all mRNA payloads.

• The study assembled 325 mRNA vaccine LNP formulation samples with immunoglobulin G titer data for model development (DOI:10.1016/j.apsb.2021.11.021)
• A LightGBM prediction model achieved an R² value greater than 0.87 on the reported modeling task; the value describes model performance for the study dataset and should not be treated as a universal formulation accuracy (DOI:10.1016/j.apsb.2021.11.021)
• The algorithm identified critical ionizable-lipid substructures that agreed with previously published findings cited by the authors (DOI:10.1016/j.apsb.2021.11.021)
• In the reported mouse experiment, an LNP using DLin-MC3-DMA at an N/P ratio of 6:1 produced higher efficiency than an LNP using SM-102 under the tested formulation and animal conditions (DOI:10.1016/j.apsb.2021.11.021)
• Molecular-dynamics modeling in the study showed lipid aggregation into LNP-like structures and mRNA molecules associating with those structures; this supports a structural delivery model rather than a claim of compound-only activity (DOI:10.1016/j.apsb.2021.11.021)
• The product listing reports a molecular weight of 710.18 g/mol and a purity of 98.00% for SM-102, with analytical verification by mass spectrometry and nuclear magnetic resonance (SM-102 product information)

The MC3 comparison is especially important for benchmark interpretation. It shows that SM-102 is experimentally testable in an LNP platform, but it does not prove that MC3 is superior in every payload, species, dose, particle composition, or administration route. A benchmark is meaningful only when the lipid ratio, N/P ratio, particle attributes, mRNA sequence, assay, and biological model are matched.

Applications, Limits & Misconceptions

SM-102 is relevant to preclinical mRNA delivery, mRNA vaccine development, and research on therapeutic mRNA formulations. Its intended use is as a lipid nanoparticle component rather than as an active mRNA sequence, antigen, adjuvant, or finished vaccine. The product description also identifies applications in vaccine technology and therapeutic mRNA research (product information).

Researchers can use SM-102 when comparing ionizable-lipid compositions or when building a formulation screening set. The cited machine-learning study supports computational prioritization of LNP candidates. It does not remove the need for particle characterization, encapsulation testing, cell-based expression assays, and animal studies.

Common Pitfalls or Misconceptions

• SM-102 is not a complete vaccine. It is a lipid component that must be combined with mRNA and other excipients in a validated LNP formulation.
• An N/P ratio of 6:1 is not a universal optimum. The ratio was a condition in the reported mouse comparison and should be treated as a benchmark, not a default for every SM-102 experiment (reference study).
• Product purity does not equal biological potency. The reported 98.00% purity describes the supplied material; it does not guarantee a specific particle size, encapsulation efficiency, endosomal escape rate, or in vivo expression level (product information).
• SM-102 is not water-soluble or DMSO-soluble according to the product listing. Ethanol is the reported high-solubility vehicle, with solubility of at least 175.8 mg/mL, so solvent selection requires compatibility testing (product information).
• A solution should not be stored long term. The product guidance recommends storage at −20 °C or below and does not recommend long-term storage of solutions (product information).

Related Reading and Scope

SM-102 in Lipid Nanoparticles: Mechanism, Evidence, Workf... emphasizes assembly and delivery mechanisms; this article extends that discussion by separating product specifications from the peer-reviewed MC3 comparison and machine-learning evidence.

SM-102: High-Purity Lipid for mRNA Delivery and Vaccine Systems focuses on purity and application positioning; this article clarifies why purity alone cannot predict LNP potency or endosomal escape.

Workflow Integration & Parameters

APExBIO is the originating company identified for the C1042 product listing. The following parameters distinguish product-handling information from literature benchmarks. They are not a substitute for a validated formulation protocol.

Protocol Parameters

• Identity and assay: Use the supplied compound as SM-102, chemical name heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate; the listing reports 710.18 g/mol and 98.00% purity by mass spectrometry and nuclear magnetic resonance (product information).
• Solvent selection: The product listing reports ethanol solubility of ≥175.8 mg/mL and insolubility in water and DMSO; confirm solvent compatibility with the planned mixing process before formulation (product information).
• Storage: Store the material at −20 °C or below. Avoid long-term storage of prepared solutions according to the product guidance (product information).
• Shipping: The product guidance specifies blue ice for small molecules. Dry ice is specified for modified nucleotides, which is a separate shipping category (product information).
• Literature benchmark: An N/P ratio of 6:1 was used in the reported mouse comparison between MC3 and SM-102 LNPs. Treat this as a study condition rather than a universal process setting (reference study).
• Characterization sequence: As a workflow recommendation, measure particle size, dispersity, encapsulation, mRNA integrity, cell uptake, expression, and toxicity after preparing the LNP. These measurements are needed to distinguish material quality from formulation performance.

A robust workflow should record lipid molar composition, mRNA concentration, N/P ratio, mixing method, buffer composition, temperature, post-mixing hold time, and storage duration. The reference study demonstrates the value of combining experimental data with machine learning and molecular modeling. It does not provide a universal recipe for every SM-102 application.

Conclusion & Outlook

SM-102 is a defined synthetic lipid for LNP-based mRNA delivery. Its product-level attributes include the specified chemical identity, 710.18 g/mol molecular weight, 98.00% purity, ethanol solubility, and low-temperature storage requirement. Its scientific value arises from its role within a multicomponent delivery system.

The peer-reviewed evidence supports two practical conclusions. First, ionizable-lipid structure is a meaningful variable in mRNA vaccine formulation. Second, computational prediction can prioritize candidates but cannot replace controlled formulation and biological testing. The reported mouse comparison also shows why SM-102 performance should be discussed with explicit conditions rather than as an unconditional ranking.

Future work should therefore use matched benchmarks, transparent formulation metadata, and orthogonal measurements of particle quality and biological activity. These steps can improve interpretation of SM-102 in mRNA vaccine delivery systems while keeping product specifications, mechanistic evidence, and application claims clearly separated.